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Venous thromboembolism (VTE), includ-
ing deep-vein thrombosis (DVT) of the
lower limbs and pulmonary embolism
(PE), occurs with an incidence of approxi-
mately one per 1,000 annually in adult
populations (1). The onset of VTE may be
provoked in some individuals by the expo-
sure to a number of major risk factors in-
cluding surgical procedures, prolonged im-
mobilisation, trauma or fractures. In the
presence of such risk factors, which are
most of the times identified in hospitalised
patients, adequate thromboprophylactic
strategies are highly recommended, since
PE remains the most common preventable
cause of in-hospital death. To improve the
correct identification of patients requiring
prophylaxis and to offer the optimal pro-
phylactic treatment, additional informa-
tion on the presence of concomitant risk
factors such as advanced age, obesity,
underlying inflammatory or infectious dis-
eases, or cancer, to name a few, is usually
collected.
VTE also shows a considerable long-
term risk of recurrences. Prospective co-
hort studies have found an overall cumu-
lative incidence of recurrent VTE of about
17% after two years, and up to about 30%
after 8–10 years (2, 3). This risk of recur-
rence is highly heterogeneous, and the defi-
nition of the individual risk is generally
based on the identification of triggering
factors. It is usually accepted to stratify pa-
tients based on the presence of permanent
provoking factors (e.g. cancer) or transient
provoking factors which commonly in-
clude, in addition to those mentioned
above, pregnancy and the use of oral
contraceptives. This simple categorisation
of VTE patients is useful since it offers an
easy stratification of the different risks of
long-term recurrence of the disease: after
one year from stopping secondary preven-
tion with anticoagulant therapy, the cumu-
lative incidence of recurrent VTE is ex-
pected to be low if the event was associated
with a transient risk factor (4) and very
high if the event occurred in association
with cancer (5). Although this categori-
sation is practical and is proposed by inter-
national clinical guidelines on the optimal
duration of secondary prevention of VTE
(6), it presents some clear drawbacks. First,
within the group of patients with VTE sec-
ondary to major, transient risk factors, the
risk of recurrence varies between patients
with a non-surgical risk factor and patients
with a surgical risk factor (4), thus suggest-
ing the need for a more detailed definition
of the individual risk despite the transient
nature of the provoking factor. Second, this
categorization leaves a non-negligible pro-
portion of patients defined as “unpro-
voked” or “idiopathic”, ranging between
25% and 50% or more, according to the de-
sign of the studies (7–9). This large popu-
lation has an estimated risk of recurrence
which lies between that of the low risk cat-
egories and that of the very high risk
groups, such as patients with cancer (10),
but clearly presents a high heterogeneity of
individual risk profiles, thus suggesting the
need to improve patients’ stratification.
Because VTE is best understood as a
multicausal disease resulting from the
complex interaction between congenital
and acquired risk factors (11), we believe
there is still room to improve this categori-
sation of VTE patients by including in the
individual assessment some additional,
non-major risk factors, as we do when de-
ciding prophylactic strategies in hospita-
lised patients.
Several of these risk factors have in fact
been associated with the onset of VTE, in-
cluding increasing age (12), traditional car-
diovascular risk factors and the metabolic
syndrome (13, 14), smoking (15), endo-
crine disorders (16, 17), and mild throm-
bophilia (18), among others. Because of
their rather high prevalence in the general
population, the concomitant action of
these minor risk factors may also be impor-
tant in the pathogenesis of VTE and in the
definition of the risk of recurrence.
In this issue of Thrombosis and Hae-
mostasis, Tichelaar et al. performed an ex-
tensive and timely updated systematic re-
search of the literature in which they evalu-
ated the role of several infective and inflam-
matory diseases as risk factors for VTE
(19). The authors were able to summarise
the results of 31 studies of general good
quality. The results of this study showed
that the presence of some of these diseases
including inflammatory bowel disease,
ANCA-associated vasculitis, infections
and, more specifically, pneumonia and uri-
nary tract infections, are associated with an
increased risk of venous thrombosis, and
the results were consistent across different
studies.
As expected, this association was stron-
gest when the time between the exposure
and the outcome was short, that is when the
inflammatory or infectious disease was ex-
perienced recently or while an inflamma-
tory or auto-immune disease was active
(flare-up).
An association was also observed be-
tween human immunodeficiency virus
(HIV) infection and VTE. However,
whether this association depends on the in-
fection itsself or it is due to the use of highly
active anti-retroviral therapy or to the high
prevalence of other traditional risk factors
in these patients remains to be established
(20). On the other hand, the role of other
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potential risk factors including sarcoidosis,
coeliac disease, or cytomegalovirus and
Chlamydia infections was less clear since
the results of single studies were more con-
flicting. Although some effects of cyto-
megalovirus or other agents on the coagu-
lation system have been described (21),
their association with VTE remains to be
established.
The results of the study by Tichelaar et
al. are clinically relevant because they pro-
vide additional evidence on the role of
minor and less known risk factors on the
pathogenesis of VTE. If on the one hand the
need for primary prophylaxis of VTE in pa-
tients with acute infections or active
chronic inflammatory diseases is well es-
tablished in the concomitant presence of
major risk factors such as immobilisation,
surgery, or delivery with caesarean section,
the role of these and other minor risk fac-
tors on the risk of recurrent VTE is less
clear. However, obesity has been found to
be associated with an increased risk of re-
currence (hazard ratio 1.6, 95% confidence
interval [CI] 1.1–2.4) (22) and a recent
study on more than 1,300 patients with a
first episode of unprovoked VTE found a
higher risk of recurrence in patients with
inflammatory bowel disease as compared
to patients without (relative risk 2.5, 95%
CI 1.4–4.2) after adjustment for age, sex,
factor V Leiden mutation, prothrombin
mutation, factor VIII level, duration of
anticoagulation and body mass index (23).
These observations are biologically
plausible. Minor risk factors that are tran-
sient in nature, such as an acute infection,
induce a temporary hypercoagulable state
which contributes to the index event, but
which disappears over time reducing the
individual risk of recurrence. This risk may
rise again in case of relapsing infections,
thus suggesting the need for adequate
thromboprophylaxis only during this time
frame. Conversely, conditions that are as-
sociated with a persistent inflammation
such as chronic inflammatory disorders,
but also such as obesity, may expose pa-
tients to a persistent hypercoagulable state
and thus to a persistently increased risk of
recurrences. For these reasons, we believe
that a careful evaluation of all minor risk
factors is needed also when deciding the
optimal duration of secondary prevention
after a first episode of VTE and that future
studies should help to revise the current
definition of “unprovoked” or “idiopathic”
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